

Section 1 Identifying Inform	nation	
1. Given Name (First Name) Leonard	2. Surname (Last Name) Altman	3. Date 15-November-2016
4. Are you the corresponding author?	Yes 📝 No	Corresponding Author's Name Parameswaren Nair
5. Manuscript Title A Pilot Randomized Clinical Trial of me	epolizumab in COPD with	Eosinophilic Bronchitis
6. Manuscript Identifying Number (if you ki ERJ-02250-2016	now it)	
	COCKST PROMISE A BANK MAN COCKST AND	
Section 2 The Work Under C	onsideration for Publ	ication
		n a third party (government, commercial, private foundation, etc.) for late monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of inter	rest? Yes 📝 No	
Section 3. Bodows was a	activities outside the	
(A)	Alpha agus a chaille ag Maria e tha a sealach ag shill a bhaile a' ghleach	in engage para na piganak a sanakan sanak para na anak masa anak anak anak anak anak anak anak a
of compensation) with entitles as descr	ribed In the Instructions. I	hether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by ere present during the 36 months prior to publication.
Are there any relevant conflicts of inter	rest? Yes Vo	
szekniva niválaháktonlokálásanbanná szándánt.		
Section 4: Intellectual Prope	rty — Patents & Copyr	ights
Do you have any patents, whether plan	nned, pending or issued, i	oroadly relevant to the work? Yes No



Section 5 Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6: Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Altman has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	ation	
1. Given Name (First Name) Angira	2. Surname (Last Name) Dasgupta	3. Date 16-November-2016
4. Are you the corresponding author?	Yes V No	Corresponding Author's Name Parameswaran Nair
5. Manuscript Title A pilot randomized clinical trial of mepo	olizumab in COPD with eo	sinophilic bronchitis
6. Manuscript Identifying Number (if you kn ERJ-02250-2016	now it)	
Section 2. The Work Under Co	onsideration for Public	cation —
		a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere	est? Yes ✓ No	
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	bed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Proper	ty Patents & Copyri <u>c</u>	ghts
Do you have any patents, whether plant	ned, pending or issued, br	oadly relevant to the work? Yes Vo



Section 5. Polotionabing not asygned above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Dasgupta has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	nation		
1. Given Name (First Name) Thomas	2. Surname (Last Name) Wight		3. Date 15-November-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Na Parameswaran Nair	me
Manuscript TitleA pilot randomized clinical trial of mep	olizumab in COPD with eo	sinophilic bronchitis	
6. Manuscript Identifying Number (if you kr ERJ-02250-2016	now it)		
Section 2. The Work Under C	onsideration for Publi	cation	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)?			
Are there any relevant conflicts of interest	est? Yes No		
S xi 2			
Section 3. Relevant financial	activities outside the s	submitted work.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the instructions. Us	se one line for each entity; a	add as many lines as you need by
Are there any relevant conflicts of intere	est? ☐ Yes 🗸 No		
Section 4. Intellectual Proper	rty Patents & Copyric	ghts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work?	? Yes 🗸 No



Section 5. Poloticaching and reconstate
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
D. Wisheld and the second seco
Dr. Wight has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Fernando	2. Surname (Last Name) Aleman Paramo	3. Date 15-November-2016
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Professor Parameswaran Nair
5. Manuscript Title A pilot randomized clinical trial of mepo	olizumab in COPD with ec	osinophilic bronchitis
6. Manuscript Identifying Number (if you kr	now it)	
Did you or your institution at any time rece	g but not limited to grants, d	ication n a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descri	ibed in the instructions. U port relationships that we	nether you have financial relationships (regardless of amount lse one line for each entity; add as many lines as you need by ere present during the 36 months prior to publication .
Section 4. Intellectual Proper	rty Patents & Copyri	ghts
Do you have any patents, whether plan	ned, pending or issued, b	roadly relevant to the work? Yes V No

Aleman Paramo 2



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Aleman Paramo has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	nation	
Given Name (First Name) Grace	2. Surname (Last Name) Parraga	3. Date 15-November-2016
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Param Nair
5. Manuscript Title ERJ-02250-2016		
6. Manuscript Identifying Number (if you k ERJ-02250-2016	now it)	
Social		
Section 2. The Work Under C	Consideration for Pub	lication
		m a third party (government, commercial, private foundation, etc.) for data monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of inter	rest? Yes V No	
Section 3. Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ribed in the instructions. I	hether you have financial relationships (regardless of amount Use one line for each entity; add as many lines as you need by ere present during the 36 months prior to publication .
Are there any relevant conflicts of inter	rest?	
Section 4. Intellectual Prope	rty Patents & Copyr	ights
Do you have any patents, whether plar	nned, pending or issued, l	oroadly relevant to the work? Yes Vo



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Parraga has nothing to disclose.

Evaluation and Feedback

 ${\bf Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.}$



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Colm	2. Surname (Last Name) Boylan	3. Date 15-November-2016
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Parameswaran Nair
Manuscript TitleA pilot randomized clinical trial of mepo	olizumab in COPD with eo	sinophilic bronchitis
6. Manuscript Identifying Number (if you kr ERJ-02250-2016	now it)	
		
	onsideration for Public	
statistical analysis, etc.)?	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Are there any relevant conflicts of intere	est? Yes ✓ No	
Section 3. Relevant financial	activities outside the s	
Place a check in the appropriate boxes in	n the table to indicate who	ether you have financial relationships (regardless of amount
clicking the "Add +" box. You should rep	bed in the instructions. Us port relationships that wer	e present during the 36 months prior to publication.
Are there any relevant conflicts of intere	st? Yes ✓ No	
Section 4.		
Do you have any patents, whether plann	ty Patents & Copyrig	
, and any parama, meetici pium	ica, periality of issued, pro	oadly relevant to the work? Yes Vo



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Boylan has nothing to disclose.

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$



Section 1. Identifying Inform	mation					
1. Given Name (First Name) Dante	2. Surname (Last Name) Capaldi	3. Date 15-November-2016				
4. Are you the corresponding author?	Yes Vo	Corresponding Author's Name Dr Parameswaran Nair				
5. Manuscript Title A pilot randomized clinical trial of mepolizumab in COPD with eosinophilic bronchitis						
6. Manuscript Identifying Number (if you ki ERJ-02250-2016	now it)					
Section 2.		·				
Did you or your institution at any time rece	onsideration for Public eive payment or services from	a third party (government, commercial, private foundation, etc.) for at a monitoring board, study design, manuscript preparation,				
statistical analysis, etc.)? Are there any relevant conflicts of interest.		ta monitoring board, study design, manuscript preparation,				
Section 3. Relevant financial	activities outside the s	ubmitted work.				
of compensation) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount e one line for each entity; add as many lines as you need by e present during the 36 months prior to publication.				
Section 4. Intellectual Proper	ty Patents & Copyrig	hts.				
Do you have any patents, whether plann	ned, pending or issued, bro	padly relevant to the work? Yes No				



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
D. Capaldi has nothing to disclose.
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$



Section 1. Identifying Inform	nation						
1. Given Name (First Name) Katherine	2. Surname (Last Name) Radford	3. Date 21-November-2016					
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Parameswaran Nair					
5. Manuscript Title A pilot randomized clinical trial of mepolizumab in COPD with eosinophilic bronchitis							
6. Manuscript Identifying Number (if you ki ERJ-02250-2016	now it)						
Did you or your institution at any time rece	g but not limited to grants, da	cation a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,					
Section 3. Relevant financial	activities outside the s	submitted work.					
of compensation) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.					
Section 4. Intellectual Proper	ty Patents & Copyric	lhts					
Do you have any patents, whether plans	ned, pending or issued, br	oadly relevant to the work? Yes Vo					



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Ms. Radford has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	aation						
1. Given Name (First Name) Melanie	2. Surname (Last Name) Kjarsgaard	3. Date 21-November-2016					
4. Are you the corresponding author?	Yes 🗸 No	Corresponding Author's Name Parameswaran Nair					
5. Manuscript Title A pilot randomized clinical trial of mepolizumab in COPD with eosinophilic bronchitis							
6. Manuscript Identifying Number (if you kn ERJ-02250-2016	ow it)						
	onsideration for Public						
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, dat	a third party (government, commercial, private foundation, etc.) for a monitoring board, study design, manuscript preparation,					
Are there any relevant connicts of intere	st?						
Section 3. Relevant financial a	activities outside the s	abmitted work.					
of compensation) with entities as describ	oed in the instructions. Use ort relationships that were	ther you have financial relationships (regardless of amount one line for each entity; add as many lines as you need by present during the 36 months prior to publication.					
Section 4. Intellectual Propert	y Patents & Copyrigl	nts					
Do you have any patents, whether plann	ed, pending or issued, bro	adly relevant to the work? Yes V No					



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below): No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Ms. Kjarsgaard has nothing to disclose.

Evaluation and Feedback



Section 1. Identifying Inform	ation			
1. Given Name (First Name) Parameswaran	2. Surname (Last Na Nair	nme)		3. Date 19-November-2016
4. Are you the corresponding author?	✓ Yes No			
5. Manuscript Title A pilot randomized clinical trial of mepo	olizumab in COPD w	ith eosinophilic b	ronchitis	
6. Manuscript Identifying Number (if you kn ERJ-02250-2016	ow it)			
Section 2.		·		
The Work Under Co	nsideration for F	ublication		
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)?	/e payment or service but not limited to gra	s from a third party nts, data monitorin	(government, g board, study	, commercial, private foundation, etc.) for design, manuscript preparation,
Are there any relevant conflicts of interes		No		
If yes, please fill out the appropriate info Excess rows can be removed by pressing	rmation below. If yo the "X" button.	u have more thai	n one entity p	press the "ADD" button to add a row.
Name of Institution/Company	Grant? Personal Fees?	Non-Financial Support?	Other	Comments
GSK	V		as rela	a study investigator for expenses ated to the conduct of the study
Section 3. Relevant financial a	ctivities outside	the submitted	work.	
Place a check in the appropriate boxes in of compensation) with entities as describ clicking the "Add +" box. You should repo	ed in the instruction	ns. Use one line fo	or each entity	y; add as many lines as you need by
Are there any relevant conflicts of interes		No	-	•
If yes, please fill out the appropriate infor	mation below.			
Name of Entity	Grant Personal	Non-Financial Support	Other ? C	omments
λZ	V		for	3 clinical trials
lovartis			for	1 clinical trial
eva			for	1 clinical trial



Name of Entity	Grant?	Personal Fees 🖁	Non-Financial Support	Other 🖁	Comments
Sanofi	V				for 1 clinical trial
Roche		✓			consultation
- Eeva		~			consultation
Novartis		/			honorarium for lecture
- y y parentes, initiati	ici piarrica, periar	19 01 13300	u, broadiy releval	iii to the	work? Yes ✓ No
Are there other relationships or	ps not covered a activities that reade	i bove ers could p	erceive to have i		work? Yes No
Section 5. Relationships or potentially influencing, what your Yes, the following relationships or potentials in the section of the section o	ps not covered a activities that reade u wrote in the subn hips/conditions/circo	Ibove ers could p nitted wor umstances	erceive to have in k? s are present (exp	nfluenced	d, or that give the appearance of
Section 5. Relationships or potentially influencing, what yo	ps not covered a activities that reade u wrote in the subn hips/conditions/circo	Ibove ers could p nitted wor umstances	erceive to have in k? s are present (exp	nfluenced	d, or that give the appearance of

Nair



Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Nair reports grants from GSK during the conduct of the study; grants from AZ, grants from Novartis, grants from Teva, grants from Sanofi, personal fees from Roche, personal fees from Teva, personal fees from Novartis, outside the submitted work; and I have provided consultation to a university spin off company, Cellometrics, that has a sputum filtration device.

Evaluation and Feedback



Section 1. Identifying Info	rmation	32.450 mm		
1. Given Name (First Name) Paul	2. Surnar O'Byrne	ne (Last Name)	3. Date 15-November-2016
4. Are you the corresponding author?	Yes	√ No	Corresponding Author's Param Nair	Name
5. Manuscript Title A pilot randomized clinical trial of mo	epolizumab ir	n COPD with	eosinophilic bronchitis	
6. Manuscript Identifying Number (if you	ı know it)			
			and the second s	
Section 2. The Work Under	Considerat	ion for Pub	lication	
Did you or your institution at any time re any aspect of the submitted work (includ statistical analysis, etc.)?	ing but not lim	t or services fro ited to grants,	m a third party (government, data monitoring board, study	commercial, private foundation, etc.) fo design, manuscript preparation,
Are there any relevant conflicts of intelligence of the liftyes, please fill out the appropriate in Excess rows can be removed by press	نے nformation b	ـــــ elow. If you h	ave more than one entity p	ress the "ADD" button to add a row.
Name of Institution/Company	Grant \$\tilde{\gamma}\$	Personal N	on-Financial Other Co	omments
Section 3. Relevant financia	al activities	outside the	submitted work.	
Place a check in the appropriate boxe of compensation) with entities as desclicking the "Add +" box. You should r	cribed in the i	instructions. I	Jse one line for each entity	add as many lines as you need by
Are there any relevant conflicts of inte	erest? 🗸 Y	es No	p	months prior to publication.
If yes, please fill out the appropriate in	nformation be	elow.		
Name of Entity	Grant [?]		on-Financial Other Co	omments
traZeneca	V	V		sultancy fees; research funding
niesi		/	Con	sultancy and lecture fees
ovartis	√			



Name of Entity	Grant ?	Personal Fees	Non-Financial	Other	Comments
Boehringer Ingelheim		✓			Advisory board participation
GSK		V			Advisory board participation
MedImmune		V			Advisory board participation
Merck		V			Advisory board participation
Amgen	✓				Research funding
Genentech	✓				Research funding
Axican	✓				Research funding
Do you have any patents, whether planned Section 5. Relationships not co Are there other relationships or activities potentially influencing, what you wrote in Yes, the following relationships/conditions/circo At the time of proposition and the stime of propositions and the stime of propositions.	overed at that read in the substitions/circ	ng or issued above lers could p mitted work cumstances tes that pres	d, broadly releva erceive to have in k? are present (exp sent a potential c	nfluenced plain belo conflict of	d, or that give the appearance of w):
At the time of manuscript acceptance, journals may ask authors to On occasion, journals may ask authors to Section 6. Disclosure Statemen	disclose f	ask author urther info	s to confirm and rmation about re	, if necess ported re	eary, update their disclosure statements. Plationships.
Based on the above disclosures, this form below.					
Dr. O'Byrne reports grants and personal fe fees from Boehringer Ingelheim, personal from Amgen, grants from Genentech, gra	l fees fror	n GSK, pers	onal fees from M	edlmmu	ne, personal fees from Merck, grants



Evaluation and Feedback